Optison

(Albumin Human)

Phase 3Small molecule

GGE Healthcare

Optison is one of 25 small molecule programs targeting Pneumonia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

PneumoniaActive, not recruiting

PneumoniaPhase 3

Active, not recruiting

Competition

Competitive Landscape

547 competitors in Pneumonia

#DrugCompanyPhaseTrials

Optison

GGE Healthcare

Phase 3

1 2

Prevacid

Takeda

Preclinical

1 3

Neutrexin

WWest Japan Thoracic Oncology Group

Preclinical

12 4

Zantac 150

CChattem

Preclinical

2 5

Alka-Seltzer

AAbbott

Preclinical

1 6

Pepcid

KKenvue Brands

Preclinical

1 7

Aciphex

Akero Therapeutics

Preclinical

1 8

Mucinex

AAultman Health Foundation

Preclinical

1 9

Tagamet

DDT MedTech, LLC

Preclinical

1 10

Protonix

WWyeth-Lederle Vaccines

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Prospective1 trial

The Acute Burn ResUscitation Multicenter Prospective Trial

Unknown status·AAmerican Burn Association·N/A·NCT04356859·400 enrolled

Pneumonia1 trial

Effect of Albumin Administration in Hypoalbuminemic Hospitalized Patients With Community-acquired Pneumonia.

Terminated·JJordi Carratala·Phase 3·NCT04071041·39 enrolled

Acute Lymphoblastic Leukemia1 trial

Effect of Early Administration of Albumin 20% Versus Crystalloid

Recruiting·EEgymedicalpedia·N/A·NCT06370078·46 enrolled

MPA1 trial

Compare the Diuretic Effect With Furosemide vs Furosemide and Albumin Combined in Cirrhotic Patients

Terminated·RRush University Medical Center·Phase 4·NCT04216784·21 enrolled

Regulatory

FDA Approval Timeline[4]

Dec 31, 1997

OPTISON

NDA NDA020899

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Albumin Human. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Albumin Human compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Albumin Human. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA020899). U.S. Food & Drug Administration.
[5]
SEC EDGAR — GE Healthcare company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GGE Healthcare

Optison

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Prospective1 trial

Pneumonia1 trial

Acute Lymphoblastic Leukemia1 trial

MPA1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News